The role of IL-1β in the early tumor cell-induced angiogenic response

Journal of Immunology

Volumn 190, Issue 7, 2013, Pages 3500-3509

  Carmi, Yaron ^a   Dotan, Shahar ^a   Rider, Peleg ^a   Kaplanov, Irena ^a   White, Malka R ^a   Baron, Rona ^a   Abutbul, Shai ^a   Huszar, Monica ^b   Dinarello, Charles A ^c   Apte, Ron N ^a   Voronov, Elena ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1BETA; RECOMBINANT PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BONE MARROW CELL; CANCER CELL; CELL ACTIVATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; CYTOKINES; DISEASE PROGRESSION; GENE EXPRESSION; INTERLEUKIN-1BETA; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MYELOID CELLS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84875425449     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202769     Document Type: Article

References (45)

1. Apte, R. N., and E. Voronov. 2008. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol. Rev. 222: 222-241.
2. Balkwill, F., and A. Mantovani. 2010. Cancer and inflammation: implications for pharmacology and therapeutics. Clin. Pharmacol. Ther. 87: 401-406.
3. Demaria, S., E. Pikarsky, M. Karin, L. M. Coussens, Y. C. Chen, E. M. El-Omar, G. Trinchieri, S. M. Dubinett, J. T. Mao, E. Szabo, et al. 2010. Cancer and inflammation: promise for biologic therapy. J. Immunother. 33: 335-351.
4. Grivennikov, S. I., F. R. Greten, and M. Karin. 2010. Immunity, inflammation, and cancer. Cell 140: 883-899.
5. Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell 144: 646-674.
6. Witz, I. P. 2009. The tumor microenvironment: the making of a paradigm. Cancer Microenviron. 2(Suppl 1): 9-17.
7. Allavena, P., and A. Mantovani. 2012. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin. Exp. Immunol. 167: 195-205.
8. Coffelt, S. B., C. E. Lewis, L. Naldini, J. M. Brown, N. Ferrara, and M. De Palma. 2010. Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am. J. Pathol. 176: 1564-1576.
9. Ferrara, N. 2010. Role of myeloid cells in vascular endothelial growth factorindependent tumor angiogenesis. Curr. Opin. Hematol. 17: 219-224.
10. Gabrilovich, D. I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12: 253-268.
11. Laurent, J., C. Touvrey, F. Botta, F. Kuonen, and C. Ruegg. 2011. Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells. Int. J. Dev. Biol. 55: 527-534.
12. Murdoch, C.,M.Muthana, S. B. Coffelt, and C. E. Lewis. 2008. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8: 618-631.
13. Qian, B. Z., and J. W. Pollard. 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.
14. Ruffell, B., N. I. Affara, and L. M. Coussens. 2012. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 33: 119-126.
15. Chung, A. S., and N. Ferrara. 2011. Developmental and pathological angiogenesis. Annu. Rev. Cell Dev. Biol. 27: 563-584.
16. Folkman, J. 2002. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29(6, Suppl 16): 15-18.
17. Kerbel, R. S. 2008. Tumor angiogenesis. N. Engl. J. Med. 358: 2039-2049.
18. Potente, M., H. Gerhardt, and P. Carmeliet. 2011. Basic and therapeutic aspects of angiogenesis. Cell 146: 873-887.
19. Bergers, G., and L. E. Benjamin. 2003. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3: 401-410.
20. Ellis, L. M., and D. J. Hicklin. 2008. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8: 579-591.
21. Grunewald, M., I. Avraham, Y. Dor, E. Bachar-Lustig, A. Itin, S. Jung, S. Chimenti, L. Landsman, R. Abramovitch, and E. Keshet. 2006. VEGFinduced adult neovascularization: recruitment, retention, and role of accessory cells. [Published erratum appears in 2006. Cell 126: 811.] Cell 124: 175-189.
22. Song, X., Y. Krelin, T. Dvorkin, O. Bjorkdahl, S. Segal, C. A. Dinarello, E. Voronov, and R. N. Apte. 2005. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J. Immunol. 175: 8200-8208.
23. Song, X., E. Voronov, T. Dvorkin, E. Fima, E. Cagnano, D. Benharroch, Y. Shendler, O. Bjorkdahl, S. Segal, C. A. Dinarello, and R. N. Apte. 2003. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J. Immunol. 171: 6448-6456.
24. Voronov, E., D. S. Shouval, Y. Krelin, E. Cagnano, D. Benharroch, Y. Iwakura, C. A. Dinarello, and R. N. Apte. 2003. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 100: 2645-2650.
25. Bunt, S. K., P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2006. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176: 284-290.
26. Nakao, S., T. Kuwano, C. Tsutsumi-Miyahara, S. Ueda, Y. N. Kimura, S. Hamano, K. H. Sonoda, Y. Saijo, T. Nukiwa, R. M. Strieter, et al. 2005. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 betainduced neovascularization and tumor growth. J. Clin. Invest. 115: 2979-2991.
27. Saijo, Y., M. Tanaka, M. Miki, K. Usui, T. Suzuki, M. Maemondo, X. Hong, R. Tazawa, T. Kikuchi, K. Matsushima, and T. Nukiwa. 2002. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J. Immunol. 169: 469-475.
28. Schmid, M. C., C. J. Avraamides, P. Foubert, Y. Shaked, S. W. Kang, R. S. Kerbel, and J. A. Varner. 2011. Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. Cancer Res. 71: 6965-6975.
29. Shibuya, M. 2006. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9: 225-230, discussion 231.
30. Lohela, M., M. Bry, T. Tammela, and K. Alitalo. 2009. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 21: 154-165.
31. Kaplan, R. N., R. D. Riba, S. Zacharoulis, A. H. Bramley, L. Vincent, C. Costa, D. D. MacDonald, D. K. Jin, K. Shido, S. A. Kerns, et al. 2005. VEGFR1- positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827.
32. Li, C., B. Liu, Z. Dai, and Y. Tao. 2011. Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC). Cancer Biol. Ther. 12: 872-880.
33. Muramatsu, M., S. Yamamoto, T. Osawa, and M. Shibuya. 2010. Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth. Cancer Res. 70: 8211-8221.
34. Horai, R., M. Asano, K. Sudo, H. Kanuka, M. Suzuki, M. Nishihara, M. Takahashi, and Y. Iwakura. 1998. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187: 1463-1475.
35. Carmi, Y., E. Voronov, S. Dotan, N. Lahat, M. A. Rahat, M. Fogel, M. Huszar, M. R. White, C. A. Dinarello, and R. N. Apte. 2009. The role of macrophagederived IL-1 in induction and maintenance of angiogenesis. J. Immunol. 183: 4705-4714.
36. Voronov, E., E. Reich, S. Dotan, P. Dransh, I. Cohen, M. Huszar, M. Fogel, H. K. Kleinman, R. M. White, and R. N. Apte. 2010. Effects of IL-1 molecules on growth patterns of 3-MCA-induced cell lines: an interplay between immunogenicity and invasive potential. J. Immunotoxicol. 7: 27-38.
37. Shchors, K., E. Shchors, F. Rostker, E. R. Lawlor, L. Brown-Swigart, and G. I. Evan. 2006. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev. 20: 2527-2538.
38. Mantovani, A., and A. Sica. 2010. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22: 231-237.
39. Tu, S., G. Bhagat, G. Cui, S. Takaishi, E. A. Kurt-Jones, B. Rickman, K. S. Betz, M. Penz-Oesterreicher, O. Bjorkdahl, J. G. Fox, and T. C. Wang. 2008. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14: 408-419.
40. Fischer, C., B. Jonckx, M. Mazzone, S. Zacchigna, S. Loges, L. Pattarini, E. Chorianopoulos, L. Liesenborghs, M. Koch, M. De Mol, et al. 2007. Anti- PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463-475.
41. Shojaei, F., X. Wu, C. Zhong, L. Yu, X. H. Liang, J. Yao, D. Blanchard, C. Bais, F. V. Peale, N. van Bruggen, et al. 2007. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450: 825-831.
42. Crawford, Y., I. Kasman, L. Yu, C. Zhong, X. Wu, Z. Modrusan, J. Kaminker, and N. Ferrara. 2009. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15: 21-34.
43. Lazarus, A., and E. Keshet. 2011. Vascular endothelial growth factor and vascular homeostasis. Proc. Am. Thorac. Soc. 8: 508-511.
44. Bar, D., R. N. Apte, E. Voronov, C. A. Dinarello, and S. Cohen. 2004. A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J. 18: 161-163.
45. Lewis, A. M., S. Varghese, H. Xu, and H. R. Alexander. 2006. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J. Transl. Med. 4: 48.